



2929 Walnut Street, Suite 1700
Philadelphia, PA 19104
Email: us.340B@gsk.com

December 19, 2025

Notice to 340B Covered Entities Located in New Mexico - Update to GSK's 340B Contract Pharmacy Policy Effective January 1, 2026

Dear Valued 340B Customer:

I am writing to inform you that GlaxoSmithKline (GSK) is updating its 340B Contract Pharmacy Policy that will alter its approach to distributing and accessing products purchased at the 340B price.

To ensure compliance with New Mexico state law requirements (H.B. 78), GSK is implementing changes to its Contract Pharmacy Policy (effective since May 1, 2023).

Effective January 1, 2026, GSK will make the following modifications to its Policy for 340B Federally Qualified Health Center and Federally Qualified Health Center Look-alike covered entities (entity types CH, FQHCLA, FQHC638) located in New Mexico:

- New Mexico-based CH, FQHCLA, and FQHC638 covered entities will be able to place "Bill to/Ship to" replenishment orders through all their HRSA designated contract pharmacies located within New Mexico, for products not part of a GSK limited pharmacy network.
- For GSK specialty/oncology products part of a limited pharmacy network, New Mexico-based CH, FQHCLA, and FQHC638 covered entities can designate unlimited contract pharmacies that are part of GSK's limited pharmacy network. Specialty/oncology designated contract pharmacies must be listed on the HRSA OPA database as a covered entity contract pharmacy (see network below).
- GSK will allow New Mexico-based CH, FQHCLA, and FQHC638 covered entities' "Bill to/Ship to" replenishment orders on or after January 1, 2026, associated with the above policy exceptions.

GSK continues to monitor state level 340B contract pharmacy requirements and may make additional modifications to the above requirements, including re-instituting its May 1, 2023 Policy.

If you have questions regarding the changes to GSK's 340B Contract Pharmacy Policy, please contact GSK at support@340Besp.com.



2929 Walnut Street, Suite 1700
Philadelphia, PA 19104
Email: us.340B@gsk.com

GSK Limited Pharmacy Networks (as of 30 June 2025)

| GSK Limited Pharmacy Network | Benlysta | Nucala | Zejula | Flolan | Ojjaara |
|--|----------|--------|--------|--------|---------|
| AcariaHealth, Inc. | X | X | | | |
| Accredo Health Group, Inc. | X | X | X | X | |
| Walgreens Specialty Pharmacy | X | X | | | |
| Amber Specialty Pharmacy | X | | | | |
| Meijer Specialty Pharmacy | X | | | | |
| Biologics, Inc. | | | X | | X |
| Caremark, LLC | X | X | X | X | |
| CenterWell Pharmacy | X | X | | | |
| BioPlus Specialty Pharmacy Services, LLC | X | X | | | |
| Prime Therapeutics | X | | | | |
| Optum Rx | X | X | X | | |
| Reliance Rx | X | | | | |
| Senderra Rx | X | | | | |
| Onco360 | | | | | X |

X indicates the GSK product eligible to be dispensed from the given pharmacy